Crohn's Disease, Healthy, Ulcerative Colitis
Conditions
Keywords
Ulcerative Colitis, Healthy Controls, Crohn's Disease
Brief summary
The daily requirement of threonine, an essential amino acid, will be evaluated in healthy adult males and in adult males with Crohn's Disease or ulcerative colitis using the indicator amino acid oxidation (IAAO) method. Participants will consume specially formulated diets with varying levels of threonine.
Detailed description
Threonine is an essential amino acid which must be obtained from the diet. It is a component of mucin. Mucin, in turn, is a key protein in the mucous membrane that protects the lining of the intestine. Inflammatory bowel disease (IBD) is a group of inflammatory conditions that affect the colon and small intestine. IBD primarily includes ulcerative colitis (UC) and Crohn's disease (CD). In UC, the inflammation is usually in the colon whereas in CD inflammation may occur anywhere along the digestive tract. Studies in animals have shown that more threonine is used when there is inflammation in the intestine. The threonine requirement in healthy participants and in IBD patients will be determined using the indicator amino acid oxidation method. The requirement derived in healthy participants will be compared to that derived in patients with IBD. Each participant will take part in two x 3 day study periods. The first two days are called adaptation days where the subjects will consume a liquid diet specially designed for him. The diet will be consumed at home. It contains all vitamins, minerals, protein and all other nutrients required. On the third day, the participant will come to the Hospital for Sick Children in Toronto. Subjects will consume hourly meals for a total of 8 meals and a stable isotope 13C-phenylalanine. Breath and urine samples will be collected to measure the oxidation of phenylalanine from which the threonine requirement will be determined.
Interventions
OTHERThreonine
Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
Sponsors
The Hospital for Sick Children
Mount Sinai Hospital, Canada
Société des Produits Nestlé (SPN)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
(healthy controls): * Male age 18 - 40 years of age * Having obtained his (or his legal representative's) written informed consent. * Normally nourished and without any inter-current illness. * Absence of an active inflammatory process in the past month.
Exclusion criteria
(healthy controls): * Subject who cannot be expected to comply with the study procedures. * Currently participating or having participated in another clinical study during the last 4 weeks prior to the beginning of this study. Inclusion Criteria: Crohn's Disease and Ulcerative Colitis * Male age 18 - 40 years of age * Having obtained his (or his legal representative's) Written Informed Consent. * For both conditions, stable disease state and not malnourished per the treating physician. * CD: Harvey Bradshaw Index (HBI) ≤ 8, disease location: evidence of ileal and or colon inflammatory involvement, no known strictures * UC: Mayo Score ≤ 7 (or Partial Mayo Score ≤5) * No tube feeding - Subjects must be treated and followed by the Gastroenterology team at Mt. Sinai Hospital, Toronto.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Threonine requirement in those with Crohn's Disease, ulcerative colitis and in healthy controls determined using the indicator amino acid oxidation method | 2 years |
Countries
Canada
Outcome results
None listed